One pill to rule them all? combo diabetes drug tested in china

NCT ID NCT06327815

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single pill containing two diabetes drugs (dapagliflozin and metformin) works as well as taking them separately in Chinese adults with type 2 diabetes. Over 24 weeks, 633 participants were randomly assigned to either the combo pill or the separate pills. The main goal was to see if the combo pill is non-inferior in lowering blood sugar (HbA1c) and to check patient satisfaction and adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Research Site

Beijing, 100020, China
Research Site

Beijing, 100050, China
Research Site

Beijing, 100076, China
Research Site

Beijing, 102218, China
Research Site

Changsha, 410005, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 402260, China
Research Site

Chuxiong, 675000, China
Research Site

Dalian, 116001, China
Research Site

Dingzhou, 562100, China
Research Site

Fuyang, 236400, China
Research Site

Guangzhou, 510180, China
Research Site

Guangzhou, 510515, China
Research Site

Guiyang, 550044, China
Research Site

Hefei, 230012, China
Research Site

Jiangyin, 214400, China
Research Site

Jiyuan, 459003, China
Research Site

Kunming, 650032, China
Research Site

Nanchang, 330006, China
Research Site

Nanning, China
Research Site

Nantong, 226001, China
Research Site

Panjin, 124000, China
Research Site

Qingdao, 266200, China
Research Site

Quanzhou, 362000, China
Research Site

Rui’an, 325200, China
Research Site

Shenzhen, 518101, China
Research Site

Suzhou, 215500, China
Research Site

Taiyuan, 030001, China
Research Site

Tianjin, 300134, China
Research Site

Weifang, 261035, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430010, China
Research Site

Yibin, 610500, China
Research Site

Zhengzhou, 450052, China
Research Site

Zhuji, 311899, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.